Matrix metalloproteinase inhibitors

@article{Brown1998MatrixMI,
  title={Matrix metalloproteinase inhibitors},
  author={Peter D. Brown},
  journal={Angiogenesis},
  year={1998},
  volume={1},
  pages={142-154}
}
Matrix metalloproteinases (MMPs) are a family of structurally related enzymes that are capable of degrading a wide variety of extracellular matrix proteins. In addition to the role played by these enzymes in normal tissue remodeling, MMPs have been implicted in the pathogenesis of diseases such as rheumatoid arthritis and multiple sclerosis. In cancer increased MMP activity may facilitate tumor invasion, metastasis and tumor angiogenesis. Expression of high levels of MMPs in certain… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 49 extracted citations

Secreted cathepsin L generates endostatin from collagen XVIII.

The EMBO journal • 2000
View 4 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-10 of 98 references

A phase I clinical trial of the matrix metalloproteinase inhibitor, marimastat, administered concurrently with carboplatin to patients with relapsed ovarian cancer (abstr)

H Thomas, M. Adams
Eur J Cancer • 1997
View 1 Excerpt

A phase I study of the matrix metalloproteinase (MMP) inhibitor AG3340 given in single doses to healthy volunteers

MA Collier, GJ Yuen, SK Bansal
Proc Am Ass Cancer Res • 1997
View 2 Excerpts

360 patient meta-analysis of studies of marimastat, a novel matrix metalloproteinase inhibitor

A Millar, P. Brown
Ann Oncol 1996; • 1996

A dose-®nding study of marimastat, an oral matrix metalloproteinase inhibitor, in patients with advanced ovarian cancer

C Poole, M Adams, V Barley
Ann Oncol • 1996

Similar Papers

Loading similar papers…